Figma Shares Indicated To Open $105/$110
ROCHESTER, NEW YORK - Syntec Optics Holdings, Inc. (NASDAQ:OPTX), a $58.7 million market cap company showing strong momentum with a 10.34% return last week according to InvestingPro, has announced its involvement in the development of non-incisional optics-based solutions aimed at correcting age-related near vision loss. This condition, presbyopia, is estimated to affect 128 million Americans, with traditional treatments including glasses, contact lenses, and surgery.
The company’s advanced optical manufacturing capabilities are being utilized to support less invasive alternatives for presbyopia treatment. Matt Carey, head of business development and delivery at Syntec Optics, expressed the company’s pride in applying its expertise to enhance the quality of life for millions through safer and more convenient treatment options.
The global market for myopia and presbyopia treatment, valued at USD 20.3 billion in 2025, is expected to grow further. Non-incisional optical solutions are emerging as a promising market segment, potentially offering reduced risks and faster recovery times compared to conventional surgical interventions. Syntec Optics appears positioned to capitalize on this opportunity, with current revenue of $29.39 million and 4.36% growth in the last twelve months. InvestingPro analysis suggests the stock is currently fairly valued, with additional metrics and insights available to subscribers.
Syntec Optics, headquartered in Rochester and operating for over two decades, has recently introduced new products including satellite optics for communication and lightweight night vision goggle optics for defense. The company maintains a healthy financial position with a current ratio of 1.34, while its negative beta of -1.28 indicates the stock often moves counter to market trends - a potential diversification benefit for investors. Discover more strategic insights with InvestingPro, which offers 7 additional ProTips for OPTX. The company’s commitment to healthcare innovation is underscored by its support for the development of technologies addressing unmet needs in vision care.
The press release includes forward-looking statements, which are subject to risks, uncertainties, and other factors that could cause actual results to differ from those projected. These statements are based on current expectations and assumptions and are not guarantees of future performance.
Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their date. Syntec Optics does not undertake to update these statements except as required by law. This article is based on a press release statement from Syntec Optics.
In other recent news, Syntec Optics Holdings, Inc. announced securing defense orders valued at approximately $5.2 million for components used in advanced night vision goggles. The company has already delivered products worth nearly $0.9 million, reflecting its ongoing contribution to a key defense program. Syntec Optics is also ramping up its production of optomechanicals by nearly 50% to fulfill orders totaling around $2.4 million, with expectations of reaching an annual production value close to $4 million. Additionally, the company has secured follow-on orders worth $2.1 million for advanced optics in next-generation military scopes, with deliveries scheduled through 2026. Syntec Optics has made significant progress in developing advanced optics for data centers and military applications, with a pre-production batch of new optical connectivity products successfully produced in Q1 2025. In corporate developments, the company announced the resignation of board member Joseph Mohr due to disagreements over operations and policies, though further details were not disclosed. These recent developments highlight Syntec Optics’ active role in advancing military and data center technologies while navigating changes in its governance structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.